AbbVie Inc. (NYSE: ABBV) and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology. The collaboration will integrate AbbVie's expertise in oncology and immunology with Tentarix's proprietary Tentacles™ platform.
AbbVie is looking to sell at least $13 billion of corporate bonds to help fund its acquisitions of ImmunoGen and Cerevel Therapeutics, Bloomberg News reported on Wednesday, citing people with knowledge of the matter. AbbVie did not immediately respond to Reuters' request for a comment. In December, AbbVie announced back-to-back acquisitions - a $8.7 billion plan to buy Cerevel and its $10.1 billion deal for ImmunoGen, which was recently completed.
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.